{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:00:12Z","timestamp":1793228412875,"version":"4.5.0"},"reference-count":261,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100018925","name":"Health Commission of Henan Province","doi-asserted-by":"publisher","award":["222102310101"],"award-info":[{"award-number":["222102310101"]}],"id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018925","name":"Health Commission of Henan Province","doi-asserted-by":"publisher","award":["242102311116"],"award-info":[{"award-number":["242102311116"]}],"id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Diagnostic Pathology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.semdp.2025.150916","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T06:48:34Z","timestamp":1747896514000},"page":"150916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Role of the bone marrow microenvironment in multiple myeloma: Impact of niches on drug resistance mechanisms"],"prefix":"10.1016","volume":"42","author":[{"given":"Lijie","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew Y.","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C Cameron","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanliang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6754-0480","authenticated-orcid":false,"given":"Mingyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.semdp.2025.150916_bib0001","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.18632\/oncotarget.1497","article-title":"Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms","volume":"4","author":"Abdi","year":"2013","journal-title":"Oncotarget"},{"issue":"7","key":"10.1016\/j.semdp.2025.150916_bib0002","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0003","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/sj.leu.2404466","article-title":"Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma","volume":"21","author":"Arnulf","year":"2007","journal-title":"Leukemia"},{"issue":"24","key":"10.1016\/j.semdp.2025.150916_bib0004","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1182\/blood-2011-09-380410","article-title":"Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features","volume":"119","author":"Azab","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semdp.2025.150916_bib0005","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1182\/blood-2014-02-558742","article-title":"CXCR7-dependent angiogenic mononuclear cell trafficking regulates tumor progression in multiple myeloma","volume":"124","author":"Azab","year":"2014","journal-title":"Blood"},{"issue":"32","key":"10.1016\/j.semdp.2025.150916_bib0006","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.21.00443","article-title":"Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14)","volume":"39","author":"Bahlis","year":"2021","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.semdp.2025.150916_bib0007","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127807","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","volume":"5","author":"Bailur","year":"2019","journal-title":"JCI insight"},{"issue":"Supplement 1","key":"10.1016\/j.semdp.2025.150916_bib0008","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2022-162395","volume":"140","author":"Bal","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0009","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.cell.2018.03.006","article-title":"Metazoan microRNAs","volume":"173","author":"Bartel","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0010","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML\/MDS and multiple myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"22","key":"10.1016\/j.semdp.2025.150916_bib0011","doi-asserted-by":"crossref","first-page":"11283","DOI":"10.18632\/oncotarget.2207","article-title":"Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4\/CXCL12 axis and promote their polarization toward the M2 phenotype","volume":"5","author":"Beider","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.semdp.2025.150916_bib0012","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/183602","article-title":"Multiple myeloma macrophages: pivotal players in the tumor microenvironment","volume":"2013","author":"Berardi","year":"2013","journal-title":"J Oncol"},{"issue":"10297","key":"10.1016\/j.semdp.2025.150916_bib0013","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.semdp.2025.150916_bib0014","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2005-09-3671","article-title":"In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma","volume":"107","author":"Beyer","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semdp.2025.150916_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e33091","article-title":"Pathways to therapy resistance: the sheltering effect of the bone marrow microenvironment to multiple myeloma cells","volume":"10","author":"Bhowmick","year":"2024","journal-title":"Heliyon"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0016","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3322\/caac.21252","article-title":"Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back","volume":"64","author":"Bianchi","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"10.1016\/j.semdp.2025.150916_bib0017","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood"},{"issue":"30","key":"10.1016\/j.semdp.2025.150916_bib0018","doi-asserted-by":"crossref","first-page":"48732","DOI":"10.18632\/oncotarget.8982","article-title":"The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential","volume":"7","author":"Bieghs","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.semdp.2025.150916_bib0019","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/path.1027","article-title":"The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies","volume":"196","author":"Bingle","year":"2002","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.semdp.2025.150916_bib0020","first-page":"131","article-title":"IMiD resistance in multiple myeloma: current understanding of the underpinning biology and clinical impact","volume":"142","author":"Bird","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semdp.2025.150916_bib0021","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/blood-2002-09-2907","article-title":"Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma","volume":"101","author":"Bisping","year":"2003","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.semdp.2025.150916_bib0022","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Blad\u00e9","year":"2011","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"issue":"7","key":"10.1016\/j.semdp.2025.150916_bib0023","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.ccell.2024.05.026","article-title":"IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma","volume":"42","author":"Bolomsky","year":"2024","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.semdp.2025.150916_bib0024","doi-asserted-by":"crossref","first-page":"IJH39","DOI":"10.2217\/ijh-2021-0017","article-title":"Adhesion molecules in multiple myeloma oncogenesis and targeted therapy","volume":"11","author":"Bou Zerdan","year":"2022","journal-title":"Int J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.semdp.2025.150916_bib0025","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00262-014-1589-9","article-title":"FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells","volume":"63","author":"Braga","year":"2014","journal-title":"Cancer Immunol Immunother: CII"},{"key":"10.1016\/j.semdp.2025.150916_bib0026","first-page":"S33","article-title":"Multiple myeloma","volume":"480","author":"Brody","year":"2011"},{"issue":"10","key":"10.1016\/j.semdp.2025.150916_bib0027","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/blood.V98.10.2992","article-title":"Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10","volume":"98","author":"Brown","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.semdp.2025.150916_bib0028","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1146\/annurev-immunol-030409-101302","article-title":"SLAM family receptors and SAP adaptors in immunity","volume":"29","author":"Cannons","year":"2011","journal-title":"Annu Rev Immunol"},{"issue":"5","key":"10.1016\/j.semdp.2025.150916_bib0029","doi-asserted-by":"crossref","first-page":"djw264","DOI":"10.1093\/jnci\/djw264","article-title":"Obesity and the transformation of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based cohort study","volume":"109","author":"Chang","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.semdp.2025.150916_bib0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2009.08.019","article-title":"Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target","volume":"16","author":"Chauhan","year":"2009","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.semdp.2025.150916_bib0031","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104","article-title":"Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B","volume":"87","author":"Chauhan","year":"1996","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0032","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12964-022-00888-2","article-title":"Tumor-associated macrophages promote epithelial-mesenchymal transition and the cancer stem cell properties in triple-negative breast cancer through CCL2\/AKT\/\u03b2-catenin signaling","volume":"20","author":"Chen","year":"2022","journal-title":"Cell Commun Signal: CCS"},{"issue":"12","key":"10.1016\/j.semdp.2025.150916_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103400","article-title":"Arl4c promotes the growth and drug resistance of pancreatic cancer by regulating tumor-stromal interactions","volume":"24","author":"Chen","year":"2021","journal-title":"iScience"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0034","doi-asserted-by":"crossref","first-page":"e2848","DOI":"10.1038\/cddis.2017.225","article-title":"Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death","volume":"8","author":"Cheteh","year":"2017","journal-title":"Cell Death Dis"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0035","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1038\/sj.leu.2402481","article-title":"Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells","volume":"16","author":"Cheung","year":"2002","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0036","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1038\/bcj.2013.18","article-title":"Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells","volume":"3","author":"Chiron","year":"2013","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.semdp.2025.150916_bib0037","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fonc.2013.00193","article-title":"Strategies to increase drug penetration in solid tumors","volume":"3","author":"Choi","year":"2013","journal-title":"Front Oncol"},{"issue":"18","key":"10.1016\/j.semdp.2025.150916_bib0038","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1158\/0008-5472.CAN-19-0343","article-title":"IL6 promotes a STAT3-PRL3 feedforward loop via SHP2 repression in multiple myeloma","volume":"79","author":"Chong","year":"2019","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.semdp.2025.150916_bib0039","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1158\/1078-0432.CCR-19-2111","article-title":"How to train your T cells: overcoming immune dysfunction in multiple myeloma","volume":"26","author":"Cohen","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0040","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2050-7771-1-8","article-title":"Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms","volume":"1","author":"Coker","year":"2013","journal-title":"Biomark Res"},{"issue":"19","key":"10.1016\/j.semdp.2025.150916_bib0041","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1038\/onc.2013.191","article-title":"Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression","volume":"33","author":"Comito","year":"2014","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.semdp.2025.150916_bib0042","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/sj.onc.1209164","article-title":"beta1-integrin-mediated signaling essentially contributes to cell survival after radiation-induced genotoxic injury","volume":"25","author":"Cordes","year":"2006","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.semdp.2025.150916_bib0043","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/sj.leu.2404621","article-title":"Bone marrow mesenchymal stem cells are abnormal in multiple myeloma","volume":"21","author":"Corre","year":"2007","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.semdp.2025.150916_bib0044","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1158\/1078-0432.CCR-24-0545","article-title":"Identification of therapy-induced clonal evolution and resistance pathways in minimal residual clones in multiple myeloma through single-cell sequencing","volume":"30","author":"Cui","year":"2024","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0045","doi-asserted-by":"crossref","first-page":"ltab018","DOI":"10.1093\/immadv\/ltab018","article-title":"A summary of current NKG2D-based CAR clinical trials","volume":"1","author":"Curio","year":"2021","journal-title":"Immunother Adv"},{"issue":"5","key":"10.1016\/j.semdp.2025.150916_bib0046","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.V93.5.1658","article-title":"Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines","volume":"93","author":"Damiano","year":"1999","journal-title":"Blood"},{"issue":"1-2","key":"10.1016\/j.semdp.2025.150916_bib0047","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/10428190009060320","article-title":"Integrin-mediated drug resistance in multiple myeloma","volume":"38","author":"Damiano","year":"2000","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1016\/j.semdp.2025.150916_bib0048","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","article-title":"Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma","volume":"95","author":"Dankbar","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0049","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.canlet.2016.04.024","article-title":"Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity","volume":"377","author":"De Veirman","year":"2016","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.semdp.2025.150916_bib0050","doi-asserted-by":"crossref","first-page":"644","DOI":"10.3390\/biomedicines11020644","article-title":"Novel adipokines and their role in bone metabolism: a narrative review","volume":"11","author":"Deepika","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.semdp.2025.150916_bib0051","doi-asserted-by":"crossref","unstructured":"Desantis V, Savino FD, Scaringella A, et al. The leading role of the immune microenvironment in multiple myeloma: a new target with a great prognostic and clinical value. 2022 2022;https:\/\/doi.org\/10.3390\/jcm11092513.","DOI":"10.3390\/jcm11092513"},{"issue":"19","key":"10.1016\/j.semdp.2025.150916_bib0052","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","article-title":"Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma","volume":"379","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0053","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1073\/pnas.1820459116","article-title":"Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma","volume":"116","author":"Ebbing","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semdp.2025.150916_bib0054","doi-asserted-by":"crossref","DOI":"10.1007\/s10585-024-10305-2","article-title":"Multiple myeloma: clinical characteristics, current therapies and emerging innovative treatments targeting ribosome biogenesis dynamics","author":"Elbahoty","year":"2024","journal-title":"Clin Exp Metastasis"},{"issue":"18","key":"10.1016\/j.semdp.2025.150916_bib0055","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1158\/0008-5472.CAN-08-4898","article-title":"Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism","volume":"69","author":"Escoubet-Lozach","year":"2009","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.semdp.2025.150916_bib0056","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41408-018-0139-7","article-title":"Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts","volume":"8","author":"Faict","year":"2018","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.semdp.2025.150916_bib0057","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1158\/0008-5472.CAN-20-1088","article-title":"Myeloma-modified adipocytes exhibit metabolic dysfunction and a senescence-associated secretory phenotype","volume":"81","author":"Fairfield","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.semdp.2025.150916_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2024.100609","article-title":"Adipocytes and metabolism: contributions to multiple myeloma","volume":"46","author":"Fairfield","year":"2024","journal-title":"J Bone Oncol"},{"issue":"7","key":"10.1016\/j.semdp.2025.150916_bib0059","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/leu.2016.358","article-title":"The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment","volume":"31","author":"Fan","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0060","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1038\/s41467-020-19932-1","article-title":"Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma","volume":"11","author":"Federico","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.semdp.2025.150916_bib0061","article-title":"CXCR4 mediates enhanced cell migration in CALM-AF10 leukemia","volume":"11","author":"Fertal","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.semdp.2025.150916_bib0062","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.892661","article-title":"Mesenchymal stromal cell-derived extracellular vesicles modulate hematopoietic stem and progenitor cell viability and the expression of cell cycle regulators in an age-dependent manner","volume":"10","author":"Fichtel","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"issue":"7","key":"10.1016\/j.semdp.2025.150916_bib0063","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1158\/1078-0432.CCR-20-2839","article-title":"VLA4-targeted nanoparticles hijack cell adhesion-mediated drug resistance to target refractory myeloma cells and prolong survival","volume":"27","author":"Fontana","year":"2021","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"38","key":"10.1016\/j.semdp.2025.150916_bib0064","doi-asserted-by":"crossref","first-page":"40496","DOI":"10.18632\/oncotarget.5800","article-title":"Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?","volume":"6","author":"Franqui-Machin","year":"2015","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.semdp.2025.150916_bib0065","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/leu.2013.254","article-title":"Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies","volume":"28","author":"Frassanito","year":"2014","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.semdp.2025.150916_bib0066","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/s41375-020-0930-x","article-title":"Development of CAR-T cell therapies for multiple myeloma","volume":"34","author":"Gagelmann","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0067","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1186\/s13018-021-02793-9","article-title":"Mechanism of exosomal miR-155 derived from bone marrow mesenchymal stem cells on stemness maintenance and drug resistance in myeloma cells","volume":"16","author":"Gao","year":"2021","journal-title":"J Orthop Surg Res"},{"issue":"4","key":"10.1016\/j.semdp.2025.150916_bib0068","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.127684","article-title":"Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma","volume":"4","author":"Garfall","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.semdp.2025.150916_bib0069","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1268421","article-title":"Acidification of intracellular pH in MM tumor cells overcomes resistance to hypoxia-mediated apoptosis in vitro and in vivo","volume":"13","author":"Gastelum","year":"2023","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.semdp.2025.150916_bib0070","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.3390\/ijms22094462","article-title":"The role of marrow microenvironment in the growth and development of malignant plasma cells in multiple myeloma","volume":"22","author":"Giannakoulas","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.semdp.2025.150916_bib0071","first-page":"2831","article-title":"Hypoxia and activated VEGF\/receptor pathway in multiple myeloma","volume":"30","author":"Giatromanolaki","year":"2010","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0072","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/cells9010095","article-title":"Angiogenic activity of cytochalasin B-induced membrane vesicles of human mesenchymal stem cells","volume":"9","author":"Gomzikova","year":"2019","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.semdp.2025.150916_bib0073","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/leu.2014.98","article-title":"Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma","volume":"28","author":"Gonsalves","year":"2014","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.semdp.2025.150916_bib0074","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/sj.leu.2402295","article-title":"Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications","volume":"15","author":"Gupta","year":"2001","journal-title":"Leukemia"},{"issue":"14","key":"10.1016\/j.semdp.2025.150916_bib0075","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1182\/blood-2016-10-745059","article-title":"Bone marrow microenvironment-derived signals induce mcl-1 dependence in multiple myeloma","volume":"129","author":"Gupta","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semdp.2025.150916_bib0076","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/path.4769","article-title":"Collaboration of cancer-associated fibroblasts and tumour-associated macrophages for neuroblastoma development","volume":"240","author":"Hashimoto","year":"2016","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.semdp.2025.150916_bib0077","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/onc.2008.385","article-title":"Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma","volume":"28","author":"Hatano","year":"2009","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.semdp.2025.150916_bib0078","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s12185-022-03297-w","article-title":"Integrin \u03b25 and \u03b27 expression in lenalidomide-resistant multiple myeloma cells","volume":"115","author":"Hattori","year":"2022","journal-title":"Int J Hematol"},{"issue":"38","key":"10.1016\/j.semdp.2025.150916_bib0079","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1038\/sj.onc.1203782","article-title":"Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)","volume":"19","author":"Hazlehurst","year":"2000","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.semdp.2025.150916_bib0080","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/cas.12096","article-title":"Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients","volume":"104","author":"Herrera","year":"2013","journal-title":"Cancer Sci"},{"issue":"3","key":"10.1016\/j.semdp.2025.150916_bib0081","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/blood-2004-01-0037","article-title":"Advances in biology of multiple myeloma: clinical applications","volume":"104","author":"Hideshima","year":"2004","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.semdp.2025.150916_bib0082","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood.V96.9.2943","article-title":"Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy","volume":"96","author":"Hideshima","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semdp.2025.150916_bib0083","first-page":"479","article-title":"Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor","volume":"90","author":"Holt","year":"2005","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.semdp.2025.150916_bib0084","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1007\/s12185-013-1293-0","article-title":"Multiple myeloma-initiating cells","volume":"97","author":"Hosen","year":"2013","journal-title":"Int J Hematol"},{"issue":"9","key":"10.1016\/j.semdp.2025.150916_bib0085","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1038\/leu.2012.80","article-title":"CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients","volume":"26","author":"Hosen","year":"2012","journal-title":"Leukemia"},{"issue":"7578","key":"10.1016\/j.semdp.2025.150916_bib0086","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nature15756","article-title":"Tumour exosome integrins determine organotropic metastasis","volume":"527","author":"Hoshino","year":"2015","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.semdp.2025.150916_bib0087","doi-asserted-by":"crossref","first-page":"4088","DOI":"10.1111\/cas.14614","article-title":"Hypoxia-inducible hexokinase-2 enhances anti-apoptotic function via activating autophagy in multiple myeloma","volume":"111","author":"Ikeda","year":"2020","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.semdp.2025.150916_bib0088","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/cas.13183","article-title":"Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma","volume":"108","author":"Ikeda","year":"2017","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.semdp.2025.150916_bib0089","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/bloodadvances.2017008847","article-title":"Hypoxia-inducible KDM3A addiction in multiple myeloma","volume":"2","author":"Ikeda","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.semdp.2025.150916_bib0090","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1158\/2326-6066.CIR-15-0296","article-title":"Myeloma drug resistance induced by binding of myeloma B7-H1 (PD-L1) to PD-1","volume":"4","author":"Ishibashi","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"Pt B","key":"10.1016\/j.semdp.2025.150916_bib0091","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.addr.2015.07.007","article-title":"Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment","volume":"99","author":"Ishii","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"issue":"17","key":"10.1016\/j.semdp.2025.150916_bib0092","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1182\/blood-2010-02-267344","article-title":"Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications","volume":"117","author":"Jakubikova","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semdp.2025.150916_bib0093","doi-asserted-by":"crossref","DOI":"10.1038\/s12276-024-01317-9","article-title":"Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2","author":"Jo","year":"2024","journal-title":"Exp Mol Med"},{"issue":"5","key":"10.1016\/j.semdp.2025.150916_bib0094","first-page":"464","article-title":"What is Multiple myeloma?","volume":"327","author":"Juliet","year":"2022","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.semdp.2025.150916_bib0095","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1172\/JCI200320530","article-title":"Epithelial-mesenchymal transition and its implications for fibrosis","volume":"112","author":"Kalluri","year":"2003","journal-title":"J Clin Investig"},{"issue":"3","key":"10.1016\/j.semdp.2025.150916_bib0096","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.semcancer.2010.04.003","article-title":"Adhesion molecules\u2013the lifelines of multiple myeloma cells","volume":"20","author":"Katz","year":"2010","journal-title":"Semin Cancer Biol"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0097","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.3892\/ijo.2013.2134","article-title":"Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells","volume":"43","author":"Kawano","year":"2013","journal-title":"Int J Oncol"},{"issue":"4","key":"10.1016\/j.semdp.2025.150916_bib0098","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1074\/jbc.M309778200","article-title":"Integrins and cytokines activate nuclear transcription factor-kappaB in human neutrophils","volume":"279","author":"Kettritz","year":"2004","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.semdp.2025.150916_bib0099","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1365-2141.2012.09154.x","article-title":"Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells","volume":"158","author":"Kim","year":"2012","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.semdp.2025.150916_bib0100","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1128\/MCB.00440-07","article-title":"Hypoxia-inducible factor 1 and dysregulated c-myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1","volume":"27","author":"Kim","year":"2007","journal-title":"Mol Cell Biol"},{"issue":"23","key":"10.1016\/j.semdp.2025.150916_bib0101","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1038\/s41388-022-02269-y","article-title":"A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response","volume":"41","author":"Kim","year":"2022","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.semdp.2025.150916_bib0102","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/nri3789","article-title":"Immune cell promotion of metastasis","volume":"15","author":"Kitamura","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"10.1016\/j.semdp.2025.150916_bib0103","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","article-title":"Anti-GPRC5D\/CD3 bispecific T-cell-redirecting antibody for the treatment of multiple myeloma","volume":"18","author":"Kodama","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cas.12314","article-title":"Clinical significance of macrophage heterogeneity in human malignant tumors","volume":"105","author":"Komohara","year":"2014","journal-title":"Cancer Sci"},{"issue":"9","key":"10.1016\/j.semdp.2025.150916_bib0105","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1182\/blood-2016-02-698092","article-title":"Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and ras pathway genes","volume":"128","author":"Kort\u00fcm","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semdp.2025.150916_bib0106","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"issue":"6168","key":"10.1016\/j.semdp.2025.150916_bib0107","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1126\/science.1244851","article-title":"Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells","volume":"343","author":"Kr\u00f6nke","year":"2014","journal-title":"Science"},{"issue":"16","key":"10.1016\/j.semdp.2025.150916_bib0108","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1182\/blood-2011-10-386789","article-title":"Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma","volume":"120","author":"Kuhn","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semdp.2025.150916_bib0109","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4049\/jimmunol.172.2.989","article-title":"Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species","volume":"172","author":"Kusmartsev","year":"2004","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.semdp.2025.150916_bib0110","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.3390\/ijms23095242","article-title":"The role of T cell immunity in monoclonal gammopathy and multiple myeloma: from immunopathogenesis to novel therapeutic approaches","volume":"23","author":"Lagreca","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"22","key":"10.1016\/j.semdp.2025.150916_bib0111","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0112","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1158\/2326-6066.CIR-15-0098","article-title":"NKG2D receptor and its ligands in host defense","volume":"3","author":"Lanier","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.semdp.2025.150916_bib0113","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.599098","article-title":"Actors on the scene: immune cells in the myeloma niche","volume":"10","author":"Leone","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.semdp.2025.150916_bib0114","doi-asserted-by":"crossref","unstructured":"Leung-Hagesteijn C, Erdmann N, Cheung G, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell 2013-09-09 2013;24(3):289-304. https:\/\/doi.org\/10.1016\/j.ccr.2013.08.009.","DOI":"10.1016\/j.ccr.2013.08.009"},{"issue":"4","key":"10.1016\/j.semdp.2025.150916_bib0115","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3324\/haematol.2019.238584","article-title":"Novel pyrrolobenzodiazepine benzofused hybrid molecules inhibit NF-\u03baB activity and synergise with bortezomib and ibrutinib in hematological cancers","volume":"106","author":"Lewis","year":"2021","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0116","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41392-020-0108-z","article-title":"Combined inhibition of notch and FLT3 produces synergistic cytotoxic effects in FLT3\/ITD+ acute myeloid leukemia","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.semdp.2025.150916_bib0117","article-title":"The emerging role of exosomes in cancer chemoresistance","volume":"9","author":"Li","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0118","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.3892\/or.2016.4714","article-title":"mir-1-mediated paracrine effect of cancer-associated fibroblasts on lung cancer cell proliferation and chemoresistance","volume":"35","author":"Li","year":"2016","journal-title":"Oncol Rep"},{"issue":"24","key":"10.1016\/j.semdp.2025.150916_bib0119","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.7150\/jca.31752","article-title":"Potential therapeutic roles of exosomes in multiple myeloma: a systematic review","volume":"10","author":"Li","year":"2019","journal-title":"J Cancer"},{"key":"10.1016\/j.semdp.2025.150916_bib0120","article-title":"Progress of tumor-associated macrophages in the epithelial-mesenchymal transition of tumor","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.semdp.2025.150916_bib0121","doi-asserted-by":"crossref","first-page":"9844","DOI":"10.18632\/oncotarget.7151","article-title":"Reelin promotes the adhesion and drug resistance of multiple myeloma cells via integrin \u03b21 signaling and STAT3","volume":"7","author":"Lin","year":"2016","journal-title":"Oncotarget"},{"issue":"23","key":"10.1016\/j.semdp.2025.150916_bib0122","doi-asserted-by":"crossref","first-page":"eabg2697","DOI":"10.1126\/sciadv.abg2697","article-title":"ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment","volume":"7","author":"Liu","year":"2021","journal-title":"Sci Adv"},{"issue":"6320","key":"10.1016\/j.semdp.2025.150916_bib0123","doi-asserted-by":"crossref","first-page":"aah7111","DOI":"10.1126\/science.aah7111","article-title":"CRISPRi-based genome-scale identification of functional long noncoding RNA loci in human cells","volume":"355","author":"Liu","year":"2017","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.semdp.2025.150916_bib0124","doi-asserted-by":"crossref","first-page":"19702","DOI":"10.1002\/jcp.28570","article-title":"Blockade of SDF-1\/CXCR4 reduces adhesion-mediated chemoresistance of multiple myeloma cells via interacting with interleukin-6","volume":"234","author":"Liu","year":"2019","journal-title":"J Cell Physiol"},{"issue":"4","key":"10.1016\/j.semdp.2025.150916_bib0125","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/cancers13040625","article-title":"The immune microenvironment in multiple myeloma: friend or foe?","volume":"13","author":"Lopes","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0126","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13045-017-0495-y","article-title":"Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair","volume":"10","author":"L\u00f3pez-Iglesias","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"6168","key":"10.1016\/j.semdp.2025.150916_bib0127","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1126\/science.1244917","article-title":"The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins","volume":"343","author":"Lu","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.semdp.2025.150916_bib0128","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1413494","article-title":"Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment","volume":"14","author":"Lu","year":"2024","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0129","article-title":"Targeting the ribosome to treat multiple myeloma","volume":"32","author":"Maclachlan","year":"2024","journal-title":"Mol Ther Oncol"},{"issue":"10","key":"10.1016\/j.semdp.2025.150916_bib0130","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1158\/0008-5472.CAN-14-3400","article-title":"Metabolic signature identifies novel targets for drug resistance in multiple myeloma","volume":"75","author":"Maiso","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.semdp.2025.150916_bib0131","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/157496","article-title":"Bone marrow microenvironment in multiple myeloma progression","volume":"2012","author":"Manier","year":"2012","journal-title":"J Biomed Biotechnol"},{"issue":"3","key":"10.1016\/j.semdp.2025.150916_bib0132","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The different mechanisms of cancer drug resistance: a brief review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv Pharm Bull"},{"issue":"7203","key":"10.1016\/j.semdp.2025.150916_bib0133","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.semdp.2025.150916_bib0134","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s00109-003-0476-1","article-title":"Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress","volume":"81","author":"Mantovani","year":"2003","journal-title":"J Mol Med"},{"key":"10.1016\/j.semdp.2025.150916_bib0135","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1476-4598-9-176","article-title":"Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells","volume":"9","author":"Markovina","year":"2010","journal-title":"Mol Cancer"},{"issue":"5","key":"10.1016\/j.semdp.2025.150916_bib0136","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3324\/haematol.2009.015628","article-title":"Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells","volume":"95","author":"Martin","year":"2010","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.semdp.2025.150916_bib0137","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0138","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2003-09-3064","article-title":"Characterization of clonogenic multiple myeloma cells","volume":"103","author":"Matsui","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0139","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1158\/0008-5472.CAN-07-3096","article-title":"Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance","volume":"68","author":"Matsui","year":"2008","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.semdp.2025.150916_bib0140","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1615\/CritRevOncog.2024053667","article-title":"The role of TAMs in the regulation of tumor cell resistance to chemotherapy","volume":"29","author":"McWhorter","year":"2024","journal-title":"Crit Rev Oncog"},{"issue":"9","key":"10.1016\/j.semdp.2025.150916_bib0141","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc2714","article-title":"Environment-mediated drug resistance: a major contributor to minimal residual disease","volume":"9","author":"Meads","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.semdp.2025.150916_bib0142","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1078-0432.CCR-07-2223","article-title":"The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance","volume":"14","author":"Meads","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.semdp.2025.150916_bib0143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2019.07.003","article-title":"Exosomes and their role in tumorigenesis and anticancer drug resistance","volume":"45","author":"Milman","year":"2019","journal-title":"Drug Resist Updates: Rev Comment Antimicrob Anticancer Chemother"},{"issue":"16","key":"10.1016\/j.semdp.2025.150916_bib0144","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2018-01-825240","article-title":"Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade","volume":"132","author":"Minnie","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.semdp.2025.150916_bib0145","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1158\/0008-5472.CAN-08-0943","article-title":"Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells","volume":"68","author":"Mishra","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.semdp.2025.150916_bib0146","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100595","article-title":"The emerging role of exosomes in multiple myeloma","volume":"38","author":"Moloudizargari","year":"2019","journal-title":"Blood Rev"},{"issue":"13","key":"10.1016\/j.semdp.2025.150916_bib0147","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2017-05-743203","article-title":"How I treat myeloma with new agents","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.semdp.2025.150916_bib0148","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood-2003-06-1984","article-title":"BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone","volume":"103","author":"Moreaux","year":"2004","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semdp.2025.150916_bib0149","doi-asserted-by":"crossref","first-page":"9159","DOI":"10.1002\/jcp.26884","article-title":"Adipokines, adiposity, and bone marrow adipocytes: dangerous accomplices in multiple myeloma","volume":"233","author":"Morris","year":"2018","journal-title":"J Cell Physiol"},{"issue":"19","key":"10.1016\/j.semdp.2025.150916_bib0150","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1158\/0008-5472.CAN-12-0213","article-title":"Frequent PVT1 rearrangement and novel chimeric genes PVT1-NBEA and PVT1-WWOX occur in multiple myeloma with 8q24 abnormality","volume":"72","author":"Nagoshi","year":"2012","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0151","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41408-020-0331-4","article-title":"Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment","volume":"10","author":"Nair-Gupta","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.semdp.2025.150916_bib0152","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056954","article-title":"Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells","volume":"8","author":"Nara","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.semdp.2025.150916_bib0153","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/blood-2003-07-2340","article-title":"Involvement of notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines","volume":"103","author":"Nefedova","year":"2004","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0154","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1038\/sj.leu.2402924","article-title":"Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms","volume":"17","author":"Nefedova","year":"2003","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.semdp.2025.150916_bib0155","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1182\/blood-2010-06-292243","article-title":"Integrin \u03b27-mediated regulation of multiple myeloma cell adhesion, migration, and invasion","volume":"117","author":"Neri","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.semdp.2025.150916_bib0156","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1038\/nm.2492","article-title":"Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth","volume":"17","author":"Nieman","year":"2011","journal-title":"Nat Med"},{"issue":"7123","key":"10.1016\/j.semdp.2025.150916_bib0157","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/nature05372","article-title":"A human colon cancer cell capable of initiating tumour growth in immunodeficient mice","volume":"445","author":"O'Brien","year":"2007","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.semdp.2025.150916_bib0158","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.3390\/cancers15174347","article-title":"Unlocking drug resistance in multiple myeloma: adipocytes as modulators of treatment response","volume":"15","author":"Ochiai","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0159","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone marrow plasma cells","volume":"199","author":"O'Connor","year":"2004","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0160","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semdp.2025.150916_bib0161","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1096\/fba.2018-00075","article-title":"The snoRNA target of t(4;14) in multiple myeloma regulates ribosome biogenesis","volume":"1","author":"Oliveira","year":"2019","journal-title":"FASEB BioAdvances"},{"issue":"22","key":"10.1016\/j.semdp.2025.150916_bib0162","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2013-06-510453","article-title":"Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile","volume":"122","author":"Paiva","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0163","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1158\/0008-5472.CAN-09-1882","article-title":"Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer","volume":"70","author":"Pan","year":"2010","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.semdp.2025.150916_bib0164","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.yexcr.2003.12.003","article-title":"Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion","volume":"294","author":"Parmo-Caba\u00f1as","year":"2004","journal-title":"Exp Cell Res"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13046-020-1535-y","article-title":"The interplay between HIF-1\u03b1 and noncoding RNAs in cancer","volume":"39","author":"Peng","year":"2020","journal-title":"J Exp Clin Cancer Res: CR"},{"key":"10.1016\/j.semdp.2025.150916_bib0166","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117503","article-title":"IGF-1 promotes multiple myeloma progression through PI3K\/akt-mediated epithelial-mesenchymal transition","volume":"249","author":"Peng","year":"2020","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0167","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry","volume":"98","author":"Pessoa de Magalh\u00e3es","year":"2013","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.semdp.2025.150916_bib0168","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/intimm\/dxh300","article-title":"Mortalin\/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis","volume":"17","author":"Pilzer","year":"2005","journal-title":"Int Immunol"},{"issue":"23","key":"10.1016\/j.semdp.2025.150916_bib0169","doi-asserted-by":"crossref","first-page":"11016","DOI":"10.1111\/jcmm.17024","article-title":"Exosomal miR-21-5p derived from bone marrow mesenchymal stem cells promote osteosarcoma cell proliferation and invasion by targeting PIK3R1","volume":"25","author":"Qi","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"25","key":"10.1016\/j.semdp.2025.150916_bib0170","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1182\/blood-2016-03-706077","article-title":"MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma","volume":"128","author":"Qiang","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semdp.2025.150916_bib0171","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/onc.2017.387","article-title":"IL6 derived from cancer-associated fibroblasts promotes chemoresistance via CXCR7 in esophageal squamous cell carcinoma","volume":"37","author":"Qiao","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.semdp.2025.150916_bib0172","doi-asserted-by":"crossref","unstructured":"Radhakrishnan V, Golla U, Kudva AK. Role of immune cells and immunotherapy in multiple myeloma. 2024 2024;.","DOI":"10.3390\/life14040461"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0173","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13045-018-0689-y","article-title":"Multiple myeloma-derived exosomes are enriched of amphiregulin (AREG) and activate the epidermal growth factor pathway in the bone microenvironment leading to osteoclastogenesis","volume":"12","author":"Raimondo","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"9","key":"10.1016\/j.semdp.2025.150916_bib0174","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.semdp.2025.150916_bib0175","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.semdp.2025.150916_bib0176","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3324\/haematol.2019.227579","article-title":"Targeting CD47\/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma","volume":"105","author":"Rastgoo","year":"2020","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.semdp.2025.150916_bib0177","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1038\/leu.2017.135","article-title":"A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells","volume":"31","author":"Ray","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.semdp.2025.150916_bib0178","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fimmu.2019.00156","article-title":"Molecular players in hematologic tumor cell trafficking","volume":"10","author":"Redondo-Mu\u00f1oz","year":"2019","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.semdp.2025.150916_bib0179","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","article-title":"Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma","volume":"29","author":"Rejeski","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1016\/j.semdp.2025.150916_bib0180","first-page":"836","article-title":"Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma","volume":"87","author":"Ria","year":"2002","journal-title":"Haematologica"},{"key":"10.1016\/j.semdp.2025.150916_bib0181","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/S0049-3848(14)50017-5","article-title":"Microenvironment and multiple myeloma spread","volume":"133","author":"Ribatti","year":"2014","journal-title":"Thromb Res"},{"key":"10.1016\/j.semdp.2025.150916_bib0182","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.semdp.2025.150916_bib0183","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.celrep.2015.06.059","article-title":"CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation","volume":"12","author":"Roccaro","year":"2015","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.semdp.2025.150916_bib0184","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/jha2.756","article-title":"Regulation of miRNA expression by \u03b14\u03b21 integrin-dependent multiple myeloma cell adhesion","volume":"4","author":"Rodr\u00edguez-Garc\u00eda","year":"2023","journal-title":"EJHaem"},{"key":"10.1016\/j.semdp.2025.150916_bib0185","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.897862","article-title":"Multiple myeloma metabolism - a treasure trove of therapeutic targets?","volume":"13","author":"Roman-Trufero","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0186","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13148-023-01433-9","article-title":"Expression of integrin \u03b2-7 is epigenetically enhanced in multiple myeloma subgroups with high-risk cytogenetics","volume":"15","author":"Roy Choudhury","year":"2023","journal-title":"Clin Epigenetics"},{"issue":"4","key":"10.1016\/j.semdp.2025.150916_bib0187","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/path.5852","article-title":"Myeloma cells regulate miRNA transfer from fibroblast-derived exosomes by expression of lncRNAs","volume":"256","author":"Saltarella","year":"2022","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.semdp.2025.150916_bib0188","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood.V97.2.346","article-title":"Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1\/fibronectin and VCAM-1","volume":"97","author":"Sanz-Rodr\u00edguez","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.semdp.2025.150916_bib0189","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.3389\/fonc.2020.01362","article-title":"Dual targeting to overcome current challenges in multiple myeloma CAR T-cell treatment","volume":"10","author":"van der Schans","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0190","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1038\/ncomms8808","article-title":"Region-specific variation in the properties of skeletal adipocytes reveals regulated and constitutive marrow adipose tissues","volume":"6","author":"Scheller","year":"2015","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.semdp.2025.150916_bib0191","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4161\/cbt.11.3.14179","article-title":"BMSC enhance the survival of paclitaxel treated squamous cell carcinoma cells in vitro","volume":"11","author":"Scherzed","year":"2011","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"10.1016\/j.semdp.2025.150916_bib0192","first-page":"218","article-title":"Evidence for cell adhesion\u2013mediated drug resistance of multiple myeloma cells in vivo","volume":"21","author":"Schmidmaier","year":"2006","journal-title":"Int J Biol Markers"},{"issue":"12","key":"10.1016\/j.semdp.2025.150916_bib0193","first-page":"4756","article-title":"Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients","volume":"61","author":"Schmielau","year":"2001","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.semdp.2025.150916_bib0194","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1080\/15384101.2017.1317408","article-title":"Hypoxia favors the generation of human plasma cells","volume":"16","author":"Schoenhals","year":"2017","journal-title":"Cell Cycle"},{"key":"10.1016\/j.semdp.2025.150916_bib0195","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.899272","article-title":"Contribution of the tumor microenvironment to metabolic changes triggering resistance of multiple myeloma to proteasome inhibitors","volume":"12","author":"Schwestermann","year":"2022","journal-title":"Front Oncol"},{"issue":"13","key":"10.1016\/j.semdp.2025.150916_bib0196","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1158\/0008-5472.CAN-07-6621","article-title":"Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells","volume":"68","author":"Serafini","year":"2008","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.semdp.2025.150916_bib0197","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/path.4103","article-title":"From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation","volume":"229","author":"Servais","year":"2013","journal-title":"J Pathol"},{"issue":"7201","key":"10.1016\/j.semdp.2025.150916_bib0198","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature07064","article-title":"IRF4 addiction in multiple myeloma","volume":"454","author":"Shaffer","year":"2008","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0199","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1586\/ehm.09.55","article-title":"Environmental-mediated drug resistance: a target for multiple myeloma therapy","volume":"2","author":"Shain","year":"2009","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"10.1016\/j.semdp.2025.150916_bib0200","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/0008-5472.CAN-08-2419","article-title":"Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation","volume":"69","author":"Shain","year":"2009","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0201","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00109-015-1345-4","article-title":"Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities","volume":"94","author":"Shay","year":"2016","journal-title":"J Mol Med"},{"issue":"4","key":"10.1016\/j.semdp.2025.150916_bib0202","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1535-6108(03)00058-8","article-title":"Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells","volume":"3","author":"Sherman-Baust","year":"2003","journal-title":"Cancer Cell"},{"issue":"112","key":"10.1016\/j.semdp.2025.150916_bib0203","first-page":"3995","article-title":"Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma","author":"Sho","year":"2021","journal-title":"Cancer Sci"},{"issue":"7015","key":"10.1016\/j.semdp.2025.150916_bib0204","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature03128","article-title":"Identification of human brain tumour initiating cells","volume":"432","author":"Singh","year":"2004","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.semdp.2025.150916_bib0205","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/leu.2017.287","article-title":"JAM-a as a prognostic factor and new therapeutic target in multiple myeloma","volume":"32","author":"Solimando","year":"2018","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0206","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/icb.2013.17","article-title":"NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors","volume":"91","author":"Spear","year":"2013","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.semdp.2025.150916_bib0207","first-page":"8","article-title":"NKG2D ligands as therapeutic targets","volume":"13","author":"Spear","year":"2013","journal-title":"Cancer Immun"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0208","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1515\/hmbci-2016-0012","article-title":"Bone marrow adipose tissue as an endocrine organ: close to the bone?","volume":"28","author":"Sulston","year":"2016","journal-title":"Horm Mol Biol Clin Investig"},{"issue":"24","key":"10.1016\/j.semdp.2025.150916_bib0209","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.18632\/oncotarget.26792","article-title":"Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma","volume":"10","author":"Sun","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.semdp.2025.150916_bib0210","article-title":"Cancer immunotherapy: challenges and limitations","volume":"229","author":"Taefehshokr","year":"2022","journal-title":"Pathol Res Pr"},{"issue":"2","key":"10.1016\/j.semdp.2025.150916_bib0211","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.semdp.2025.150916_bib0212","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1369\/jhc.2008.952200","article-title":"Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"57","author":"Tancred","year":"2009","journal-title":"J Histochem Cytochem: Off J Histochem Soc"},{"issue":"3","key":"10.1016\/j.semdp.2025.150916_bib0213","first-page":"878","article-title":"Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy","volume":"8","author":"Tannock","year":"2002","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0214","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1600-0609.2010.01531.x","article-title":"CXCR7: a new SDF-1-binding receptor in contrast to normal CD34(+) progenitors is functional and is expressed at higher level in human malignant hematopoietic cells","volume":"85","author":"Tarnowski","year":"2010","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.semdp.2025.150916_bib0215","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.3324\/haematol.2019.221176","article-title":"IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification","volume":"105","author":"Teoh","year":"2020","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.semdp.2025.150916_bib0216","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1038\/bcj.2016.37","article-title":"Increased circulating VCAM-1 correlates with advanced disease and poor survival in patients with multiple myeloma: reduction by post-bortezomib and lenalidomide treatment","volume":"6","author":"Terpos","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.semdp.2025.150916_bib0217","doi-asserted-by":"crossref","first-page":"947","DOI":"10.3389\/fimmu.2018.00947","article-title":"NY-ESO-1 based immunotherapy of cancer: current perspectives","volume":"9","author":"Thomas","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.semdp.2025.150916_bib0218","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3389\/fphar.2015.00226","article-title":"Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells","volume":"6","author":"Tibullo","year":"2015","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0219","doi-asserted-by":"crossref","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","article-title":"Subclone-specific microenvironmental impact and drug response in refractory multiple myeloma revealed by single-cell transcriptomics","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0220","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3324\/haematol.2019.218289","article-title":"Hypoxia-induced long non-coding RNA DARS-AS1 regulates RBM39 stability to promote myeloma malignancy","volume":"105","author":"Tong","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.semdp.2025.150916_bib0221","doi-asserted-by":"crossref","first-page":"9099","DOI":"10.1007\/s13277-015-4761-8","article-title":"RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines","volume":"37","author":"Tsubaki","year":"2016","journal-title":"Tumor Biol"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0222","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/bjh.12333","article-title":"Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17A stimulation","volume":"161","author":"Tucci","year":"2013","journal-title":"Br J Haematol"},{"issue":"25","key":"10.1016\/j.semdp.2025.150916_bib0223","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/blood-2014-05-576116","article-title":"Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1","volume":"124","author":"Umezu","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0224","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ajh.2830500103","article-title":"Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44","volume":"50","author":"Vacca","year":"1995","journal-title":"Am J Hematol"},{"issue":"20","key":"10.1016\/j.semdp.2025.150916_bib0225","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1158\/0008-5472.CAN-17-0115","article-title":"HIF-2\u03b1 promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12\/CXCR4 and CCR1","volume":"77","author":"Vandyke","year":"2017","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.semdp.2025.150916_bib0226","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/17474086.2018.1548931","article-title":"Venetoclax for the treatment of multiple myeloma","volume":"11","author":"Vaxman","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"7","key":"10.1016\/j.semdp.2025.150916_bib0227","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1002\/1097-0142(20010401)91:7<1219::AID-CNCR1122>3.0.CO;2-1","article-title":"Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients","volume":"91","author":"Wallace","year":"2001","journal-title":"Cancer"},{"issue":"14","key":"10.1016\/j.semdp.2025.150916_bib0228","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.7150\/jca.30102","article-title":"High numbers of CD163+ tumor-associated macrophages correlate with poor prognosis in multiple myeloma patients receiving bortezomib-based regimens","volume":"10","author":"Wang","year":"2019","journal-title":"J Cancer"},{"issue":"41","key":"10.1016\/j.semdp.2025.150916_bib0229","doi-asserted-by":"crossref","first-page":"43992","DOI":"10.18632\/oncotarget.6083","article-title":"The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.semdp.2025.150916_bib0230","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/path.4712","article-title":"Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression","volume":"239","author":"Wang","year":"2016","journal-title":"J Pathol"},{"issue":"4","key":"10.1016\/j.semdp.2025.150916_bib0231","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2014-03-562439","article-title":"Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0232","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13045-018-0554-z","article-title":"Cell adhesion-mediated mitochondria transfer contributes to mesenchymal stem cell-induced chemoresistance on T cell acute lymphoblastic leukemia cells","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"13","key":"10.1016\/j.semdp.2025.150916_bib0233","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1182\/blood-2006-04-016980","article-title":"Optimizing immunotherapy in multiple myeloma: restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK\/ERK MAPK and neutralizing interleukin-6 in progenitor cells","volume":"108","author":"Wang","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0234","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13046-021-02209-w","article-title":"Induction of m6A methylation in adipocyte exosomal LncRNAs mediates myeloma drug resistance","volume":"41","author":"Wang","year":"2022","journal-title":"J Exp Clin Cancer res: CR"},{"key":"10.1016\/j.semdp.2025.150916_bib0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101856","article-title":"Bone marrow adipocytes is a new player in supporting myeloma cells proliferation and survival in myeloma microenvironment","volume":"40","author":"Wei","year":"2024","journal-title":"Transl Oncol"},{"issue":"22","key":"10.1016\/j.semdp.2025.150916_bib0236","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.semdp.2025.150916_bib0237","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.566599","article-title":"Single-cell sequencing of glioblastoma reveals central nervous system susceptibility to SARS-CoV-2","volume":"10","author":"Wu","year":"2020","journal-title":"Front Oncol"},{"issue":"14","key":"10.1016\/j.semdp.2025.150916_bib0238","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"6","key":"10.1016\/j.semdp.2025.150916_bib0239","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1158\/1078-0432.CCR-18-2363","article-title":"Exosome-transmitted PSMA3 and PSMA3-AS1 promote proteasome inhibitor resistance in multiple myeloma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"issue":"7","key":"10.1016\/j.semdp.2025.150916_bib0240","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41375-018-0061-9","article-title":"Mesenchymal stem cells in multiple myeloma: a therapeutical tool or target?","volume":"32","author":"Xu","year":"2018","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.semdp.2025.150916_bib0241","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41388-020-01590-8","article-title":"Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma","volume":"40","author":"Xu","year":"2021","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.semdp.2025.150916_bib0242","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","article-title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","volume":"6","author":"Yan","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.semdp.2025.150916_bib0243","article-title":"Interferon regulatory factor 4: an alternative marker for plasma cells in Daratumumab-treated patients with multiple myeloma","author":"Yang","year":"2024","journal-title":"Int J Lab Hematol"},{"issue":"8","key":"10.1016\/j.semdp.2025.150916_bib0244","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/14737140.2023.2229029","article-title":"Role of the bone marrow microenvironment in multiple myeloma treatment using CAR-T therapy","volume":"23","author":"Yao","year":"2023","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0245","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-020-00848-8","article-title":"The role of cancer-derived microRNAs in cancer immune escape","volume":"13","author":"Yi","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1016\/j.semdp.2025.150916_bib0246","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/cr.2014.122","article-title":"Profiling human protein degradome delineates cellular responses to proteasomal inhibition and reveals a feedback mechanism in regulating proteasome homeostasis","volume":"24","author":"Yu","year":"2014","journal-title":"Cell Res"},{"issue":"52","key":"10.1016\/j.semdp.2025.150916_bib0247","doi-asserted-by":"crossref","first-page":"86075","DOI":"10.18632\/oncotarget.13342","article-title":"Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy","volume":"7","author":"Yu","year":"2016","journal-title":"Oncotarget"},{"issue":"27","key":"10.1016\/j.semdp.2025.150916_bib0248","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/bloodadvances.2017010801","article-title":"Hypoxia promotes IL-32 expression in myeloma cells, and high expression is associated with poor survival and bone loss","volume":"1","author":"Zahoor","year":"2017","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.semdp.2025.150916_bib0249","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-020-00350-x","article-title":"Immune-based therapies in the management of multiple myeloma","volume":"10","author":"Zanwar","year":"2020","journal-title":"Blood Cancer J"},{"issue":"21","key":"10.1016\/j.semdp.2025.150916_bib0250","doi-asserted-by":"crossref","first-page":"10123","DOI":"10.1158\/0008-5472.CAN-07-3127","article-title":"Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts","volume":"67","author":"Zeisberg","year":"2007","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.semdp.2025.150916_bib0251","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41419-023-06108-0","article-title":"Tumor-associated macrophages confer colorectal cancer 5-fluorouracil resistance by promoting MRP1 membrane translocation via an intercellular CXCL17\/CXCL22-CCR4-ATF6-GRP78 axis","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.semdp.2025.150916_bib0252","article-title":"Natural killer cells affect the natural course, drug resistance, and prognosis of multiple myeloma","volume":"12","author":"Zhang","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.semdp.2025.150916_bib0253","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.semdp.2025.150916_bib0254","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ccell.2016.03.026","article-title":"Tight junction protein 1 modulates proteasome capacity and proteasome inhibitor sensitivity in multiple myeloma via EGFR\/JAK1\/STAT3 signaling","volume":"29","author":"Zhang","year":"2016","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.semdp.2025.150916_bib0255","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222312808","article-title":"Cytochrome P450 enzymes and drug metabolism in humans","volume":"22","author":"Zhao","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"17","key":"10.1016\/j.semdp.2025.150916_bib0256","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","article-title":"Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis","volume":"114","author":"Zheng","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semdp.2025.150916_bib0257","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/leu.2012.272","article-title":"PSGL-1\/selectin and ICAM-1\/CD18 interactions are involved in macrophage-induced drug resistance in myeloma","volume":"27","author":"Zheng","year":"2013","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.semdp.2025.150916_bib0258","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s40364-023-00538-w","article-title":"Exosome derived from tumor-associated macrophages: biogenesis, functions, and therapeutic implications in human cancers","volume":"11","author":"Zhou","year":"2023","journal-title":"Biomark Res"},{"issue":"12","key":"10.1016\/j.semdp.2025.150916_bib0259","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1007\/s00262-008-0512-7","article-title":"Immunomodulatory drugs revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation","volume":"57","author":"Zhu","year":"2008","journal-title":"Cancer Immunol Immunother: CII"},{"issue":"18","key":"10.1016\/j.semdp.2025.150916_bib0260","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.semdp.2025.150916_bib0261","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1182\/blood-2021-153747","article-title":"Identifying mechanisms associated with venetoclax resistance in multiple myeloma (MM)","volume":"138","author":"Zhu","year":"2021","journal-title":"Blood"}],"container-title":["Seminars in Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257025000528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257025000528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T02:05:12Z","timestamp":1749261912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740257025000528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":261,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0740257025000528"],"URL":"https:\/\/doi.org\/10.1016\/j.semdp.2025.150916","relation":{},"ISSN":["0740-2570"],"issn-type":[{"value":"0740-2570","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of the bone marrow microenvironment in multiple myeloma: Impact of niches on drug resistance mechanisms","name":"articletitle","label":"Article Title"},{"value":"Seminars in Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semdp.2025.150916","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150916"}}